Failure of pre-diarrheal antibiotics to prevent hemolytic uremic syndrome in serologically proven Escherichia coli O157:H7 gastrointestinal infection

Journal of Pediatrics

Volumn 135, Issue 6, 1999, Pages 768-769

  Igarashi, Takashi ^a,b   Inatomi, Jun ^a   Wake, Akiko ^a   Takamizawa, Masaru ^a   Katayama, Hajime ^a   Iwata, Tsutomu ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 MICROGLOBULIN; CEFTERAM PIVOXIL; CEPHALOSPORIN;

ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL COLONIZATION; CASE REPORT; DIARRHEA; DRUG MECHANISM; ESCHERICHIA COLI; FEMALE; GASTROINTESTINAL INFECTION; HEMOLYTIC UREMIC SYNDROME; HUMAN; HUMAN CELL; HUMAN TISSUE; PATHOPHYSIOLOGY; PRESCHOOL CHILD; PRIORITY JOURNAL;

EID: 0033498879     PISSN: 00223476     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-3476(99)70100-9     Document Type: Article

References (10)

1. 1. Neill MA. Treatment of disease due to Shiga toxin-producing Escherichia coli. In: Kaper JB, O'Brien AD, editors. Escherichia coli O157:H7 and other Shiga toxin-producing E. coli strains. Washington (DC): American Society for Microbiology; 1998. p. 357-63.
2. 2. Carter AO, Borczyk AA, Carlson JA, Harvey B, Hockin JC, Karmali MA, et al. A severe outbreak of Escherichia coli O 157:H7-associated hemorrhagic colitis in a nursing home. N Engl J Med 1987;317:1496-500.
3. 3. Slutsker I, Ries AA, Maloney K, Well JG, Greene KD, Griffin PM. A nationwide case-control study of Escherichia coli O157:H7 infection in the United States. J Infect Dis 1998;177:962-6.
4. 4. Takeda T, Yoshino K, Uchida H, Ikeda N, Tanimura M. Early use of fosfomycin for Shiga toxin-producing Escherichia coli O 157 infection reduces the risk of hemolytic-uremic syndrome. In: Kaper JB, O'Brien AD, editors. Escherichia coli O157:H7 and other Shiga toxin-producing E. coli strains. Washington (DC): American Society for Microbiology; 1998. p. 385-7.
5. 5. Higami S, Nishimoto K, Kawamura T, Tsuruhara T, Isshiki G, Ookita A. Retrospective analysis of the relationship between HUS incidence and antibiotics among patients with Escherichia coli O157 enterocolitis in the Sakai outbreak [in Japanese]. Kansenshogaku Zasshi 1998;72:266-72.
6. 6. Yoh M, Aoki T, Sakaue Y, Tsubura E, Honda T. Report of questionnaire about enterohemorrhagic Escherichia coli cases caused in the area including Sakai City in 1996 [in Japanese]. Kansenshogaku Zasshi 1997;71:1144-54.
7. 7. Kohsaka T, Tagawa M, Suzuki T, Ito H. The old and new problems of the antibiotics treatment in hemorrhagic enterocolitis and hemolytic uremic syndrome, according to Japanese epidemiological studies [in Japanese]. Nippon Rinsho 1997;55:706-15.
8. 8. Greatorex JS, Thorne GM. Humoral immune responses to Shiga-like toxins and Escherichia coli O157 lipopolysaccharide in hemolytic-uremic syndrome patients and healthy subjects. J Clin Microbiol 1994;32:1172-8.
9. 9. Richardson SE, Rotman TA, Jay V, Smith CR, Becker LE, Petric M, et al. Experimental verocytotoxemia in rabbits. Infect Immun 1992;60:4154-67.
10. 10. Taguchi T, Uchida H, Kiyokawa N, Mori T, Sato N, Horie H, et al. Verotoxins induce apoptosis in human renal tubular epithelium derived cells. Kidney Int 1998;53:1681-8.